| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from issuance of series c preferred stock | 8,500 | - |
| Cash flows provided by financing activities | 8,500 | 8,500 |
| Net increase (decrease) in cash and cash equivalents | -2,488 | 1,334 |
| Cash and cash equivalents at beginning of period | 6,105 | - |
| Cash and cash equivalents at end of period | 3,617 | - |
Biofrontera Inc. (BFRI)
Biofrontera Inc. (BFRI)